Related Experiment Video
Updated: Jan 17, 2026
10:49
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
18.6K
Pediatric Oncology
Margaret Wong1, Nicole Leibman1
1The Schwarzman Animal Medical Center, The Cancer Institute, 510 East 62nd Street, New York, NY 10065, USA.
The Veterinary Clinics of North America. Small Animal Practice
|September 19, 2025
Summary
Veterinary pediatric oncology is an understudied field. This review covers common canine pediatric tumors, their behavior, and treatment difficulties, highlighting the need for more research in young animal cancer.
Area of Science:
- Veterinary medicine
- Comparative oncology
- Pediatric oncology
Background:
- Veterinary pediatric oncology is an emerging field with limited research and case reports on tumors affecting young animals.
- A 2023 study indicated that less than 0.004% of dogs under one year old are diagnosed with neoplasia.
- Common canine pediatric tumors include cutaneous histiocytomas, papillomas, mast cell tumors, rhabdomyosarcomas, nephroblastomas, and neuroblastomas.
Purpose of the Study:
- To review the types of pediatric tumors found in veterinary medicine.
- To discuss the diverse biological behaviors of these tumors, ranging from benign to aggressive.
- To outline the challenges associated with treating pediatric tumors in animals.
Main Methods:
- Literature review of existing studies and case reports on pediatric tumors in veterinary medicine.
- Analysis of tumor types, prevalence, and behavior in young animals.
- Synthesis of information on current treatment strategies and challenges.
Main Results:
- Canine pediatric tumors encompass a range of histopathological types, including histiocytomas, papillomas, mast cell tumors, rhabdomyosarcomas, nephroblastomas, and neuroblastomas.
- These neoplasms exhibit variable clinical behaviors, from self-limiting to highly aggressive.
- Treatment approaches are often adapted from adult oncology, with specific challenges related to the pediatric population.
Conclusions:
- Veterinary pediatric oncology requires further investigation due to the unique aspects of tumor development and treatment in young animals.
- Understanding the specific characteristics of pediatric tumors is crucial for improving diagnostic accuracy and therapeutic outcomes.
- Further research is warranted to address the specific needs and challenges in managing cancer in young animals.
Related Concept Videos
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
195
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
195
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
212
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
212
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
254
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
254
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
246
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
246
01:20The Retinoblastoma Gene
4.7K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.7K
01:29Drug Dosing: Infants and Children
256
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
256